Citigroup’s bluebird bio BLUE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-7,503
| Closed | -$36.6K | – | 5659 |
|
|
2025
Q1 | $36.6K | Sell |
7,503
-896
| -11% | -$5.39K | ﹤0.01% | 4963 |
|
|
2024
Q4 | $70K | Buy |
8,399
+1,232
| +17% | +$10.8K | ﹤0.01% | 4977 |
|
|
2024
Q3 | $74.5K | Buy |
7,167
+4,742
| +196% | +$78.8K | ﹤0.01% | 4891 |
|
|
2024
Q2 | $47.7K | Buy |
2,425
+11
| +0.5% | +$220 | ﹤0.01% | 4611 |
|
|
2024
Q1 | $61.8K | Sell |
2,414
-24,251
| -91% | -$622K | ﹤0.01% | 4521 |
|
|
2023
Q4 | $736K | Sell |
26,665
-1,233
| -4% | -$75.2K | ﹤0.01% | 3102 |
|
|
2023
Q3 | $1.7M | Buy |
27,898
+1,526
| +6% | +$107K | ﹤0.01% | 2104 |
|
|
2023
Q2 | $1.74M | Sell |
26,372
-39,586
| -60% | -$2.9M | ﹤0.01% | 2342 |
|
|
2023
Q1 | $4.19M | Buy |
65,958
+41,804
| +173% | +$4.77M | ﹤0.01% | 1594 |
|
|
2022
Q4 | $3.34M | Sell |
24,154
-19,766
| -45% | -$2.78M | ﹤0.01% | 1707 |
|
|
2022
Q3 | $5.56M | Buy |
43,920
+43,314
| +7,148% | +$4.9M | ﹤0.01% | 1492 |
|
|
2022
Q2 | $50K | Sell |
606
-8,869
| -94% | -$688K | ﹤0.01% | 4531 |
|
|
2022
Q1 | $919K | Sell |
9,475
-15,898
| -63% | -$2.1M | ﹤0.01% | 3053 |
|
|
2021
Q4 | $5.07M | Buy |
25,373
+13,873
| +121% | +$3.27M | ﹤0.01% | 1819 |
|
|
2021
Q3 | $2.85M | Sell |
11,500
-1,857
| -14% | -$531K | ﹤0.01% | 2245 |
|
|
2021
Q2 | $5.53M | Buy |
13,357
+266
| +2% | +$105K | ﹤0.01% | 1818 |
|
|
2021
Q1 | $5.11M | Buy |
13,091
+7,577
| +137% | +$3.73M | ﹤0.01% | 1772 |
|
|
2020
Q4 | $3.09M | Sell |
5,514
-1,457
| -21% | -$923K | ﹤0.01% | 2447 |
|
|
2020
Q3 | $4.87M | Sell |
6,971
-71
| -1% | -$55.4K | ﹤0.01% | 1907 |
|
|
2020
Q2 | $5.57M | Buy |
7,042
+113
| +2% | +$85.2K | ﹤0.01% | 1766 |
|
|
2020
Q1 | $4.13M | Buy |
6,929
+1,573
| +29% | +$1.53M | ﹤0.01% | 1835 |
|
|
2019
Q4 | $6.09M | Buy |
5,356
+83
| +2% | +$90.2K | ﹤0.01% | 1872 |
|
|
2019
Q3 | $6.27M | Buy |
5,273
+449
| +9% | +$686K | 0.01% | 1740 |
|
|
2019
Q2 | $7.95M | Buy |
4,824
+3,396
| +238% | +$5.88M | 0.01% | 1581 |
|
|
2019
Q1 | $2.91M | Sell |
1,428
-2,145
| -60% | -$3.78M | ﹤0.01% | 2253 |
|
|
2018
Q4 | $4.59M | Sell |
3,573
-3,772
| -51% | -$5.79M | ﹤0.01% | 1884 |
|
|
2018
Q3 | $13.9M | Sell |
7,345
-13,753
| -65% | -$28.4M | 0.01% | 1073 |
|
|
2018
Q2 | $42.9M | Buy |
21,098
+19,334
| +1,096% | +$44.1M | 0.04% | 419 |
|
|
2018
Q1 | $3.9M | Buy |
1,764
+872
| +98% | +$2.22M | ﹤0.01% | 1992 |
|
|
2017
Q4 | $2.06M | Sell |
892
-2,324
| -72% | -$4.72M | ﹤0.01% | 2641 |
|
|
2017
Q3 | $5.72M | Buy |
3,216
+439
| +16% | +$613K | ﹤0.01% | 1637 |
|
|
2017
Q2 | $3.78M | Buy |
2,777
+397
| +17% | +$479K | ﹤0.01% | 1955 |
|
|
2017
Q1 | $2.8M | Sell |
2,380
-1,483
| -38% | -$1.51M | ﹤0.01% | 2156 |
|
|
2016
Q4 | $3.09M | Buy |
3,863
+1,023
| +36% | +$812K | ﹤0.01% | 2405 |
|
|
2016
Q3 | $2.49M | Sell |
2,840
-369
| -11% | -$267K | ﹤0.01% | 2308 |
|
|
2016
Q2 | $1.8M | Sell |
3,209
-595
| -16% | -$337K | ﹤0.01% | 2420 |
|
|
2016
Q1 | $2.09M | Buy |
3,804
+596
| +19% | +$366K | ﹤0.01% | 2439 |
|
|
2015
Q4 | $2.67M | Buy |
3,208
+1,015
| +46% | +$1.01M | ﹤0.01% | 2252 |
|
|
2015
Q3 | $2.43M | Buy |
2,193
+1,251
| +133% | +$2.28M | ﹤0.01% | 2272 |
|
|
2015
Q2 | $2.05M | Buy |
942
+341
| +57% | +$695K | ﹤0.01% | 2487 |
|
|
2015
Q1 | $940K | Sell |
601
-251
| -29% | -$331K | ﹤0.01% | 3136 |
|
|
2014
Q4 | $1.01M | Buy |
852
+794
| +1,369% | +$531K | ﹤0.01% | 3118 |
|
|
2014
Q3 | $27K | Sell |
58
-32
| -36% | -$14.8K | ﹤0.01% | 5705 |
|
|
2014
Q2 | $45K | Sell |
90
-254
| -74% | -$81.4K | ﹤0.01% | 5225 |
|
|
2014
Q1 | $102K | Sell |
344
-41
| -11% | -$12.4K | ﹤0.01% | 4963 |
|
|
2013
Q4 | $104K | Buy |
385
+362
| +1,574% | +$101K | ﹤0.01% | 5225 |
|
|
2013
Q3 | $8K | Buy |
+23
| New | +$8.54K | ﹤0.01% | 6274 |
|
Other funds holding BLUE
Citigroup's BLUE Position: Q2 2025 in Review
Citigroup sold out of bluebird bio (BLUE) in Q2 2025, closing a stake of 7,503 shares — an estimated $36.6K sold.
Citigroup first reported a position in BLUE in Q3 2013 and held it in 47 quarters. The position peaked at $42.9M in Q2 2018. 3 funds tracked by Wall St. Rank hold BLUE as of Q2 2025.
- Citigroup reported no remaining bluebird bio position as of Q2 2025 after selling out during the quarter.
- Citigroup sold 7,503 bluebird bio shares in Q2 2025, an estimated $36.6K.
- Citigroup first reported a position in bluebird bio in Q3 2013 and held it in 47 quarters.
- Citigroup's bluebird bio position peaked at $42.9M in Q2 2018.
- 3 funds tracked by Wall St. Rank held bluebird bio as of Q2 2025.
Based on Citigroup's 13F filing for Q2 2025, filed 11 Aug 2025.